Irritable Bowel Syndrome Market | Leading Segments, Trends, Drivers and Challenges

Market Recovery and Growth Projections 2021-2025

Global irritable bowel syndrome market is likely to post an incremental growth of $ 779.89 mn, accelerating at a CAGR of  10.09% during the forecast period. This research provides a detailed analysis of the market segments and geographic landscape. It also offers insights into the various growth factors and challenges that are likely to have a negative impact on market growth. This thorough research will equip clients with the insights necessary to plan and strategize a post-pandemic recovery plan.

Request for Our Free Sample Report for detailed Insights

Irritable Bowel Syndrome Market: Market Segments and Growth Forecasts

This research report will provide insights into the current market share of each segment along with growth projections for the next five years.

• Market is segmented by Type (IBS-D, IBS-C, and IBS-M) and Geography (North America, Europe, Asia, and ROW).
• 40% of the market growth will originate from North America during the forecast period. This report provides an accurate prediction of the contribution of all the geographic segments to the growth of the Irritable Bowel Syndrome Market size.

Irritable Bowel Syndrome Market: Trends, Drivers, Challenges

The report also offers a detailed impact analysis of various trends, drivers, and challenges that are likely to influence the market growth during the forecast period. These insights will equip clients to design a growth strategy for their business and area of operations.

• Unhealthy lifestyle habits will be a significant factor in driving the growth of the Irritable Bowel Syndrome Market.
• Increasing incidence of gastrointestinal disorders will be instrumental in driving the market growth during the forecast period.
• Counterfeit drugs is a hurdle that needs to be crossed on the path to success.

Irritable Bowel Syndrome Market: Vendor Analysis

• The market is fragmented.
• AbbVie Inc., Alfasigma Spa, Astellas Pharma Inc., AstraZeneca Plc, Bausch Health Companies Inc., Ironwood Pharmaceuticals Inc., Mallinckrodt Plc, Novartis AG, Sebela Pharmaceuticals Inc., and Teva Pharmaceutical Industries Ltd. are some of the major market participants.
• The unprecedented outbreak of COVID-19 in 2020 has had a significant impact on market segments had a ripple effect on various stakeholders. Our vendor analysis and insights will provide you with all the information required to make the most of the opportunities and plan business recovery and growth post the pandemic.

Key Areas Covered in our Report:

• Irritable Bowel Syndrome Market Split by Type
  • IBS-D
  • IBS-C
  • IBS-M
• Irritable Bowel Syndrome Market Split by Geography
  • North America
  • Europe
  • Asia
  • ROW

Customer landscape

• Customer landscape

Geographic Landscape

• Geographic segmentation
• Geographic comparison
• APAC - Market size and forecast 2020-2025
• MEA - Market size and forecast 2020-2025
• Europe - Market size and forecast 2020-2025
• North America - Market size and forecast 2020-2025
• South America - Market size and forecast 2020-2025
• Key leading countries
• Market opportunity by geography
• Market drivers
• Market challenges
• Market trends

Vendor Landscape

• Competitive scenario
• Vendor landscape
• Landscape disruption

Vendor Analysis

• AbbVie Inc.
• Alfasigma Spa
• Astellas Pharma Inc.
• AstraZeneca Plc
• Bausch Health Companies Inc.
• Ironwood Pharmaceuticals Inc.
• Mallinckrodt Plc
• Novartis AG
• Sebela Pharmaceuticals Inc.
• Teva Pharmaceutical Industries Ltd.

The report provides insights into the following FAQs:

1. What is the market CAGR?
   The market will accelerate at a CAGR of 10.09%.
    
2. What is the incremental growth of the market?
   The market is expected to grow by $ 779.89 mn through 2021-2025.
    
3. What is a key factor driving this market?
   Unhealthy lifestyle habits will drive market growth over the forecast period.
    
4. What are the key regions covered in this market research report?
   North America, Europe, Asia, and ROW are the key regions featured in this research report.
    
5. Which is the leading geographic region for this market:
   40% growth will originate from North America
    
6. Who are the leading market vendors?
   The leading vendors in this market are AbbVie Inc., Alfasigma Spa, Astellas Pharma Inc., AstraZeneca Plc, Bausch Health Companies Inc., Ironwood Pharmaceuticals Inc., Mallinckrodt Plc, Novartis AG, Sebela Pharmaceuticals Inc., and Teva Pharmaceutical Industries Ltd.
    
7. What are the market segments covered in this report?
   The market is segmented by Type (IBS-D, IBS-C, and IBS-M) and Geography (North America, Europe, Asia, and ROW)